Occam's Strategic Partnership with Geron Continues with the Placement of Head of R&D
In November 2024, Joseph Eid, MD, was placed by Occam Global as Executive Vice President, Research and Development of Geron Corporation (Nasdaq: GERN), a commercial-stage oncology biopharma.
In this role, Dr. Eid will lead the Research and Development department for the organization, including medical, clinical, and safety/pharmacovigilance teams. He will drive innovative strategies to support the commercial success of RYTELO™ and ensure ongoing research opportunities.
Dr. Eid has over twenty years of experience in medical affairs and clinical development in the biopharmaceutical industry. Recently, he led medical affairs and research at Dragonfly Therapeutics as President of Research and Development. Previously, he served as Executive Vice President and Chief Medical Officer at Luzsana Bio, a subsidiary of Hengrui Pharmaceuticals. Dr. Eid began his career in oncology drug development at Roche in 2004 before joining Merck in 2009.
Dr. Eid’s appointment marks Occam’s eighth high-profile executive placements, including the Chief Commercial Officer, Chief Financial Officer, Chief Legal Officer, Chief Business Officer, and three Board members. Geron exemplifies Occam Global as a long-term strategic partner for a public biotech company rebuilding for the commercial stage. Read more about Occam's work with Geron in our case study.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.